相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
Thuy V. Nguyen et al.
BIOMATERIALS (2014)
New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma
Antoine Galmiche et al.
CANCER LETTERS (2014)
Alternative Mammalian Target of Rapamycin (mTOR) Signal Activation in Sorafenib-resistant Hepatocellular Carcinoma Cells Revealed by Array-based Pathway Profiling
Mari Masuda et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Ramona Rudalska et al.
NATURE MEDICINE (2014)
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo et al.
LIVER CANCER (2014)
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T. Pressiani et al.
ANNALS OF ONCOLOGY (2013)
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib
D. Chen et al.
EJSO (2013)
Label-retaining liver cancer cells are relatively resistant to sorafenib
Hong-Wu Xin et al.
GUT (2013)
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Carmen Berasain
GUT (2013)
B-crystallin complexes with 14-3-3 to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
Xiao-Yong Huang et al.
HEPATOLOGY (2013)
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
Angela Gauthier et al.
HEPATOLOGY RESEARCH (2013)
The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2013)
Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?
Yu-Yun Shao et al.
Liver Cancer (2013)
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
Bo Zhai et al.
WORLD JOURNAL OF HEPATOLOGY (2013)
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma
Catia Giovannini et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
S. Hagiwara et al.
BRITISH JOURNAL OF CANCER (2012)
Molecular mechanisms of sorafenib action in liver cancer cells
Melchiorre Cervello et al.
CELL CYCLE (2012)
Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Augusto Villanueva et al.
CLINICAL CANCER RESEARCH (2012)
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
Hashem B. El-Serag
GASTROENTEROLOGY (2012)
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma
Satoshi Shimizu et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
Marie-Jose Blivet-Van Eggelpoel et al.
JOURNAL OF HEPATOLOGY (2012)
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
M. Pinter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis
Ying-Hong Shi et al.
AUTOPHAGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma
L. Chen et al.
EJSO (2011)
JNK: A double-edged sword in tumorigenesis
Francisco Javier Cubero et al.
HEPATOLOGY (2011)
Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
Kuen-Feng Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
IL-1β induces ER stress in a JNK dependent manner that determines cell death in human pancreatic epithelial MIA PaCa-2 cells
Gaurav Verma et al.
APOPTOSIS (2010)
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre et al.
LANCET ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells
D-D Li et al.
ONCOGENE (2009)
Molecular targeted therapies in hepatocellular carcinoma
Josep M. Llovet et al.
HEPATOLOGY (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
F. Fornari et al.
ONCOGENE (2008)
Statistical methods for efficiency adjusted real-time PCR quantification
Joshua S. Yuan et al.
Biotechnology Journal (2007)
dp5/HRK is a c-jun target gene and required for apoptosis induced by potassium deprivation in cerebellar granule neurons
Chi Ma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
p38α suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway
Lijian Hui et al.
NATURE GENETICS (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Mammalian MAP kinase signalling cascades
LF Chang et al.
NATURE (2001)
分享论文
